UMC Utrecht has started its initial enrollment for a study focused on discovering biomarkers for Amyotrophic Lateral Sclerosis. This research, led by Professor Dr. Leonard van den Berg and supported by VectorY Therapeutics, aims to find biomarkers that could aid in the diagnosis of ALS, track disease progression, and improve the development of new treatments.

VectorY Therapeutics is developing advanced therapies using vectorized antibodies to target neurodegenerative diseases, with its primary project, VTx-002, concentrating on TDP-43 for ALS treatment. ALS is a serious condition with a lifetime risk of approximately 1 in 400 in Western populations, characterized by the gradual degeneration of motor neurons. Unfortunately, there is no cure at present, and existing treatments only marginally prolong life.

The study will recruit 70 ALS patients in the Netherlands, collecting multiple samples of blood and cerebrospinal fluid (CSF) to identify and test potential biomarkers, including those related to TDP-43. These biomarkers are expected to deepen our understanding of ALS's underlying mechanisms and aid in developing new therapies. Results will be shared in a peer-reviewed journal, contributing to the scientific community's knowledge of ALS.

The study adheres to the principles outlined in the Declaration of Helsinki and the Medical Research Involving Human Subjects Act (WMO) and has obtained approval from the Medical Research Ethics Committee, NedMec.

VectorY, remarked, “The recent discoveries in ALS pathogenesis have enabled the development of novel therapies targeting TDP-43. Access to reliable biomarkers is crucial for developing these therapies, and our partnership with UMC Utrecht will provide the necessary longitudinal samples for this purpose.”

UMC Utrecht, commented, “Identifying biomarkers for ALS is a pivotal step for future research. This collaboration with VectorY Therapeutics will facilitate the development of objective measures that provide insights into ALS progression. Our ultimate goal is to expedite the discovery of effective treatments for ALS, and this partnership is a crucial step toward that objective.”

VTx-002 is being developed to slow ALS progression and enhance the quality of life for patients. In preclinical trials, this vectorized antibody effectively removes misfolded and aggregated TDP-43 from the cytoplasm of neuronal cells, restoring its function in the nucleus and preserving neuronal health and function.

 

Source: 

Report Abuse